EF-Tu Targeting Antibody for Infection Treatment
Application
Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections.
Key Benefits
An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections.
A research-grade antibody has been developed with animal data showing the ability to...
Published: 10/13/2023
Contributor(s): Joanna Goldberg, Dina Moustafa
|
Non-invasive Probes to Determine Efficacy of Cancer Therapies
Application
A real-time, non-invasive probe to determine the efficacy of cancer immunotherapies.
Key Benefits
Determines immunotherapy success in patients.
CAR cells can be tested before putting it back in the patients.
Simple diagnostic with readout in 30 minutes compared to 2-3 days.
Market Summary
Lymphoblastic leukemia is one of the most...
Published: 1/10/2024
Contributor(s): Anna Kellner, Khalid Salaita, Curtis Henry
|
Antisense Oligonucleotides Therapeutics Targeting Specific Tissues or Cells
Application
Antisense oligonucleotide (ASO) therapies for the treatment of rare diseases and cancer.
Key Benefits
Novel approach to ASO therapeutics that potentially improve tissue/cell targeting capabilities.
Increases the efficacy of ASOs while decrease off-target toxicity.
Potential to treat a variety of genetic diseases such as cancer, blood...
Published: 3/1/2024
Contributor(s): Jiahui Zhang, Khalid Salaita, Hanjoong Jo
|
Microfluidic and Organotypic Tumor Slice Culture Drug Testing Platform for Individualized Cancer Therapy
Application
A drug combination screening/testing platform for individualized cancer therapy.
Key Benefits
Rapid screening of effective drug combination.
Integrated tumor microenvironment.
Identifying personalized therapy for individual cancer patient.
Market Summary
Traditional two-dimensional (2D) in vitro culture models for drug development...
Published: 1/25/2024
Contributor(s): Tobey John MacDonald, Anna Kenney, Abhinav Dey, YongTae (Tony) Kim
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type of heart...
Published: 3/1/2024
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type of heart...
Published: 3/1/2024
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
C19Check: COVID-19 Severity Stratification Tool
Application
Algorithm for screening of individuals exhibiting coronavirus disease (COVID-19) symptoms.
Key Benefits
Allows mass screening of potential COVID-19 patients.
Alleviates burden on hospitals and doctors’ offices.
Reduces unnecessary interactions with individuals.
May be used in regions with low internet access.
Market Summary
Coronavirus...
Published: 7/28/2023
Contributor(s): Justin Schrager, Alexander Isakov, David Wright, Anna Yaffee, Arthur Kellermann
|
INFORMED: Instant Functional Outcomes Report for Meaningful Encounters in Dialysis
ApplicationSoftware report that records and displays the domains of physical functioning for dialysis patients to inform clinicians' shared decision making.Key BenefitsEnables longitudinal tracking of patient information on functioning over time.Displays information across multiple domains of physical functioning.Increases cooperation of patient with...
Published: 7/28/2023
Contributor(s): Laura Plantinga, Brian Jones, Ann Vandenberg, Leigh Nadel
|
Immortalized Mouse Aortic Endothelial Cell Lines
Application
Immortalized (using polyoma middle T-antigen) mouse aortic endothelial primary cell lines for studying vascular biology and pathophysiology, including cardiovascular research.
Key Benefits
Immortalized from mouse artery endothelial cells using polyoma middle T-antigen.
Validated retention of primary endothelial markers and structural...
Published: 3/1/2024
Contributor(s): Hanjoong Jo, Chih-Wen Ni, Sandeep Kumar
|
Inhibitors of MicroRNA-miR712/miR205 for the Treatment of Atherosclerosis and Other Vascular Conditions
Application
Antisense oligonucleotide inhibitors of microRNA-miR712/miR205 to prevent or treat atherosclerosis and aortic aneurysm.
Key Benefits
80% reduction on the expression of their microRNA targets.
Reduces atheroma plaque formation in a mouse model of atherosclerosis.
Provides potential non-surgical treatment for aortic aneurysm.
Market...
Published: 7/28/2023
Contributor(s): Hanjoong Jo, Chanwoo Kim, Sandeep Kumar, Dong ju Son, Haiwei Qiu, Wakako Takabe
|